Intech made co-development alliance with Twi to enter niche inhaler market of US.
Intech got the permission of clinical trials for its asthma product Duasma in China.
Intech got the preliminary approval and will submit the application of final approval for listing on OTC stock market soon.
Intech has submitted its application for IPO, and triggered its multinational clinical trials and international business development.
Intech new plant accelerates the pace and expands the capacity to fulfill the international market demand.
Intech signed the license and supply agreement with China Resources Saike Pharmaceutical, both companies will form an alliance and seize the niche market.
Intech iLEF MDI platform is praised widely and will move quickly in China market.
Intech got the qualification report of sample testing for Duasma, an inhaler product treating Asthma, and accelerate the market expansion in Taiwan and China.
Intech got the license of Duasma, an inhaler product treating Asthma, in Hong Kong and accelerate the market expansion in the area of Greater China.
Intech has launched a reliever drug of asthma Synvent in Taiwan and targets the 2.6 billion global market in the future.